Pharmaceuticals 2010, 3(4), 810-838; doi:10.3390/ph3040810
Review

Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase

1 Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay 2 Laboratorio de Química Orgánica, Instituto de Química Biológica-Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay
* Authors to whom correspondence should be addressed.
Received: 1 February 2010; in revised form: 15 March 2010 / Accepted: 19 March 2010 / Published: 25 March 2010
(This article belongs to the Special Issue Tropical Medicine)
PDF Full-text Download PDF Full-Text [638 KB, uploaded 25 March 2010 10:07 CET]
Abstract: Chagas’ disease, or American trypanosomosiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the cantidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term.
Keywords: Chagas’ disease; “hit-to-lead”; drug-likeness

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Cerecetto, H.; González, M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals 2010, 3, 810-838.

AMA Style

Cerecetto H, González M. Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase. Pharmaceuticals. 2010; 3(4):810-838.

Chicago/Turabian Style

Cerecetto, Hugo; González, Mercedes. 2010. "Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase." Pharmaceuticals 3, no. 4: 810-838.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert